B
Beat Müllhaupt
Researcher at University of Zurich
Publications - 289
Citations - 17086
Beat Müllhaupt is an academic researcher from University of Zurich. The author has contributed to research in topics: Hepatitis C & Liver transplantation. The author has an hindex of 55, co-authored 258 publications receiving 14656 citations.
Papers
More filters
Journal ArticleDOI
Same quality – higher price? The paradox of allocation: the first national single center analysis after the implementation of the new Swiss transplantation law: the ICU view
Christian E. Oberkofler,Reto Stocker,Dimitri A. Raptis,John F. Stover,Reto A. Schuepbach,Beat Müllhaupt,Philipp Dutkowski,Pierre-Alain Clavien,Markus Béchir +8 more
TL;DR: The paradox of allocation is examined in the first national single center analysis after the implementation of the new Swiss transplantation law: the ICU view.
Journal ArticleDOI
5′-Cytosine DNA-methyltransferase mRNA levels in hereditary colon carcinoma
Claude A. Jakob,Irene Guldenschuh,Rainer Hurlimann,Beat Müllhaupt,Andreas Müller,Rudolf W. Ammann,Michael Fried,Jürgen Roth +7 more
TL;DR: The findings suggest that the mRNA levels of methyltransferase cannot be used as predictive marker for screening in families affected by hereditary colon carcinoma.
Journal ArticleDOI
Effect of hepatitis B virus on steatosis in hepatitis C virus co-infected subjects: A multi-centre study and systematic review
Nicolas Goossens,C. De Vito,Alessandra Mangia,Sophie Clément,Giovanni Cenderello,Francisco Barrera,Roberta D'Ambrosio,Nicola Coppola,Rosa Zampino,Maria Stanzione,Le Adinolfi,Heiner Wedemeyer,Heiner Wedemeyer,Nasser Semmo,Beat Müllhaupt,David Semela,Raffaele Malinverni,Darius Moradpour,Markus H. Heim,Gaia Trincucci,Laura Rubbia-Brandt,Francesco Negro +21 more
TL;DR: Although the prevalence of steatosis is similar in HBV‐HCV compared to HCV subjects, the analysis suggests that there may be an inhibitory effect of HCV‐induced steatogenesis by HBV in certain subgroups of patients.
Journal ArticleDOI
1361 il28b polymorphisms linked to poor response to treatment are associated with low necroinflammatory activity and slow fibrosis progression in hcv genotype non-1-infected patients
Pierre-Yves Bochud,Stéphanie Bibert,Zoltán Kutalik,Nicolas Goossens,Beat Müllhaupt,Tilman Gerlach,Markus H. Heim,Darius Moradpour,A. Cerny,Raffaele Malinverni,J-F. Dufour,F. Negro +11 more
Journal Article
Interferon and ribavirin with or without amantadine for interferon non-responders with chronic hepatitis C. A randomized, controlled pilot study.
TL;DR: Comparing efficacy and tolerability of an interferon-alfa-2a, ribavirin and amantadine combination with an INF and RIBA combination found that RIBA and AMA does not seem to offer relevant efficacy advantages over double combination with INF andRIBA in INF non-responders with chronic hepatitis C.